Sponsors (4)
The bill aims to accelerate Lyme-related innovation and awareness through targeted incentives and collaboration, but relies on non-binding guidance and a small prize fund that may divert limited resources and risk producing short-term, commercially driven solutions rather than sustained, system-level improvements.
People with Lyme disease could see faster development and deployment of better prevention, diagnostics, and treatments through accelerated, patient-focused development efforts and prize incentives.
Patients, families, and the public could receive improved education and awareness about Lyme disease, leading to earlier recognition and treatment.
Researchers, universities, nonprofits, and small businesses gain incentives, visibility, and collaboration opportunities that may spur new diagnostics, products, and research activity on Lyme disease.
People with Lyme disease may not see meaningful change if the bill's policy statements remain non-binding and do not create new funding or enforceable timelines.
Taxpayers and patients face opportunity costs because the $5 million in prize funding and any shifted research attention could have been used for direct research grants, clinical services, or other diseases.
Prize-based competitions risk producing prototypes or startup-focused solutions rather than supporting sustained clinical trials or long-term public-health infrastructure, and if poorly designed may yield few viable products, delaying meaningful benefits.
Based on analysis of 3 sections of legislative text.
Authorizes $5 million for HHS to run prize competitions to spur patient-centered prevention, diagnosis, treatment, and public-awareness innovations for Lyme disease.
Authorizes $5 million to the Department of Health and Human Services to run prize competitions that encourage new approaches to preventing, diagnosing, and treating Lyme disease, and promotes patient-centered, rapid diagnostics and public education. Declares a federal policy to engage academia, nonprofits, industry, small businesses, entrepreneurs, and government to support innovation and awareness for Lyme disease care.
Introduced February 11, 2026 by Christopher Henry Smith · Last progress February 11, 2026